Senior Scientist, Analytical Development
- Employer
- Precision BioSciences, Inc.
- Location
- Durham, NC
- Start date
- Nov 21, 2024
View more categoriesView less categories
- Discipline
- Information Technology, Business/Data Analytics, Science/R&D, Biotechnology
- Required Education
- Doctorate/PHD/MD
- Position Type
- Full time
- Hotbed
- Bio NC
Job Details
Summary
The Senior Scientist, Analytical Development will be a key member of the CMC organization which aims to drive operational excellence for the successful development of Precision BioSciences’ Gene Therapy Products, including AAV vectors and Lipid Nanoparticle Encapsulated mRNA. The Senior Scientist, Analytical Development will be primarily responsible for developing robust control strategies and analytical methods for projects in multiple phases of development. In support of this, candidates must be able to collaborate across functions to develop process and product understanding. Ideal candidates will have experience across multiple analytical techniques, with regulatory filings and interactions, and a demonstrated ability to solve complex technical problems in a dynamic environment.
Essential Duties and Responsibilities
Reasonable accommodations may be made to enable individuals with disabilities to perform the essential functions of this position. This list contains the major duties and requirements of the job and is not all-inclusive. Incumbent(s) may be expected to perform role-related duties other than those contained in this document.
- Design, develop, and implement analytical methods for the characterization and release of gene therapy products
- Establish robust control strategies through identification and characterization of Critical Quality Attributes (CQAs), development of analytical methods through assay validation, design and execution of stability studies
- Supervise and mentor other analytical scientists driving professional growth of group members
- Contribute to authoring of regulatory submissions, including pre-submission briefing books, clinical trial applications, and responses to agency questions
- Provide technical oversight of method development/transfer and QC testing at external vendors
- Effectively interface with other functions including Quality, Regulatory, Research, Nonclinical and Clinical Development and other CMC functions (Process Development)
- Participate in quality events (OOS, OOT, laboratory investigations, CAPA, CC) as needed
- Implement technical solutions using strong problem-solving skills across multiple projects
- Demonstrate strong written and verbal communication skills
Qualifications
The requirements listed below are representative of the knowledge, skill, and/or ability required to perform this job successfully.
Required:
- PhD in Analytical Chemistry, Biochemistry, Chemistry, or related field and 8+ years of experience working in Pharma or biotech, or equivalent combination of education and experience
- Experience with regulatory submissions including pre-submission meeting briefs, Common Technology Document (CTD) authoring and Response to Questions (RtQ)
Preferred:
- Experience with analytical control strategy development from pre-FHD to commercial launch
- Experience with the development of gene therapies, cell therapies, or biologics
- Knowledge of multiple analytical techniques applicable to gene therapy products, such as ddPCR, next generation sequencing (NGS), capillary electrophoresis, UPLC, cell-based potency and ELISAs
- Ability to adapt to evolving project needs and prioritize multiple activities
- Demonstrated proficiency with the implementation of analytical Quality by Design (QbD) principles
Travel Requirements
- Minimal travel is anticipated for this position.
Location
- This is an office-based position located at the main headquarters in Durham, NC.
Precision BioSciences, Inc. (Nasdaq: DTIL), is a clinical stage biotechnology company dedicated to improving life (DTIL) with its novel and proprietary ARCUS® genome editing platform. This isn’t just a statement supporting the products that we’re developing – it’s a statement that speaks to our collective desire to do our part in improving the lives of those around us. ARCUS is a highly specific and versatile genome editing platform designed with therapeutic safety, delivery, and control in mind. Using ARCUS, Precision is developing in vivo gene correction therapies for genetic diseases. Our team includes pioneers in genome editing, leaders in business, and a full staff of talented and committed people who are excited to be a part of medical and scientific breakthroughs. For additional information, please visit www. precisionbiosciences.com
Precision BioSciences actively fosters an inclusive environment to ensure we attract and retain the best talent; we value diversity of life experiences and perspectives; and we encourage innovation in pursuit of our mission. We provide equal employment opportunities (EEO) to all employees and applicants for employment without regard to race, color, religion, gender, sexual orientation, gender identity or expression, national origin, age, disability, genetic information, marital status, amnesty, or status as a covered veteran in accordance with applicable federal, state and local laws. Precision BioSciences complies with applicable state and local laws governing non-discrimination in employment in every location in which the company has facilities. This policy applies to all terms and conditions of employment, including, but not limited to, hiring, placement, promotion, termination, layoff, recall, transfer, leaves of absence, compensation, and training.
Company
Precision BioSciences, Inc. (Nasdaq: DTIL) is a clinical stage gene editing company developing in vivo gene editing and ex vivo allogeneic CAR T therapies with its highly precise and versatile ARCUS genome editing platform. ARCUS uses sequence-specific DNA-cutting enzymes, or nucleases designed for gene knock out, as well as highly sophisticated edits for gene insertion and/or gene repair. Precision’s in vivo gene editing pipeline consists of wholly-owned preclinical candidates for primary hyperoxaluria type 1 (PBGENE-PH1), familial hypercholesteremia (PBGENE-PCSK9) and chronic hepatitis B (PBGENE-HBV). It has also partnered with Lilly to develop candidates for Duchenne muscular dystrophy and two other programs targeting the liver and CNS. Precision’s allogeneic CAR T pipeline consists of multiple investigational candidates in early-stage clinical trials, including its first and second generation CD19 targeting candidates PBCAR0191 and PBCAR19B for relapsed and/or refractory (R/R) non-Hodgkin and B-cell lymphoma patients. Precision has also prioritized development of PBCAR269A, its BCMA targeted candidate in combination with a gamma secretase inhibitor for R/R patients with multiple myeloma. Precision BioSciences and its in-house manufacturing facility for AAV, mRNA, and CAR T cells is based in Durham, North Carolina. For more information about Precision BioSciences please visit www.precisionbiosciences.com
Stock Symbol: DTIL
Stock Exchange: NASDAQ
- Website
- http://www.precisionbiosciences.com/
- Phone
- 919-314-5512
- Location
-
302 East Pettigrew Street
Durham
North Carolina
27701
United States
Get job alerts
Create a job alert and receive personalized job recommendations straight to your inbox.
Create alert